Izba (Travoprost)

Travoprost activates prostaglandin F (FP) receptors in the eye, triggering remodeling of the extracellular matrix in the ciliary muscle. This enhances uveoscleral outflow of aqueous humor, thereby decreasing intra‑ocular pressure, which is the primary therapeutic goal in glaucoma management.

The prescribed dose of Izba is determined by the treating ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact regimen should follow the prescriber’s instructions and the patient’s clinical response.

Safety of travoprost in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order Izba, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common alternative is latanoprost, another prostaglandin analog. Both agents lower intra‑ocular pressure by increasing uveoscleral outflow, but individual response and side‑effect profiles can differ. Some patients may experience less iris darkening with travoprost, while others may prefer latanoprost’s dosing convenience.

Izba should be stored at room temperature, below 25 °C, in its original bottle. Keep the container tightly closed, protect it from light and moisture, and avoid freezing. Do not refrigerate unless specifically instructed by the supplier.

Izba is applied as an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place one drop into the conjunctival sac of the prescribed eye(s). Close the eye gently for a few seconds and avoid touching the tip of the bottle to any surface.

Serious risks, though rare, include severe allergic reactions, uveitis, macular edema, and sudden vision loss. Patients should seek immediate medical attention if they experience intense eye pain, swelling, vision changes, or systemic allergic symptoms such as rash or difficulty breathing.

Izba is contraindicated in patients with active ocular infections, inflammation, or known hypersensitivity to travoprost or any component of the formulation. Caution is also advised for individuals with a history of severe ocular inflammation or those who cannot safely administer eye drops.